Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare "Least Costly Alternative" Nixed By Courts, But Could Reform Bill's IMAB Convey New Authority?

Executive Summary

A federal appeals court has upheld a lower court's determination that Medicare statutes do not allow the program to limit reimbursement for a drug under Part B to the rate for a "least costly alternative" drug
Advertisement

Related Content

Part B Reference Pricing Faces 'Clinical' As Well As 'Political' Obstacles
Part B Demo Concerns Unite Policy Experts Across Political Spectrum
Medicare’s Least Costly Alternative Policy: CMS Not Giving Up Yet
Targeting Drug Costs Will Have Minimal Impact On Federal Health Care Spending - Avalere
Medicare Part B Drug "Least Costly Alternative" Policy Rescinded By CMS
Medicare Part B Drug "Least Costly Alternative" Policy Rescinded By CMS
Medicare Part B Drug "Least Costly Alternative" Policy Rescinded By CMS
Amending IPAB: Lack Of Administrative, Judicial Review Raises Concern
With Some Rx Tweaks, Senate Bill Moves To Conference With House
With Some Rx Tweaks, Senate Bill Moves To Conference With House

Topics

Advertisement
UsernamePublicRestriction

Register

PS051803

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel